Gregory Riely

发表

KRAS mutations in non-small cell lung cancer.

W. Pao, Gregory Riely, J. Marks, 2009, Proceedings of the American Thoracic Society.

New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.

W. Travis, Gregory Riely, E. Brambilla, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

H. Varmus, M. Kris, W. Pao, 2005, PLoS medicine.

Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2014 .

Driver mutations determine survival in smokers and never‐smokers with stage IIIB/IV lung adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2012, Cancer.

Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing

W. Travis, Gregory Riely, M. Zakowski, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

C. Brennan, M. Ladanyi, M. Berger, 2019, Nature Genetics.

Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients

Donavan T. Cheng, Alexander V Penson, Benjamin E. Gross, 2017, Nature Medicine.

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

M. Kris, C. Azzoli, W. Pao, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2014, The New England journal of medicine.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

J. Engelman, Michael Thomas, A. Shaw, 2014, The New England journal of medicine.

OncoKB: A Precision Oncology Knowledge Base.

Moriah H Nissan, B. Taylor, N. Schultz, 2017, JCO precision oncology.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Masahiro Tsuboi, Iver Petersen, Hisao Asamura, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer

M. Berger, S. Lowe, J. Reis-Filho, 2017, Nature Medicine.

Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency

C. Begg, R. Shen, M. Gonen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Jeffrey W. Clark, A. Iafrate, J. Engelman, 2011, The Lancet. Oncology.

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

H. Varmus, M. Ladanyi, M. Kris, 2005, PLoS medicine.

Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

M. Ladanyi, M. Kris, E. Venkatraman, 2006, Clinical Cancer Research.

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

William Pao, Marc Ladanyi, Vincent A. Miller, 2013, Clinical Cancer Research.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Michael Thomas, Takashi Seto, Kazuhiko Nakagawa, 2013, The New England journal of medicine.

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

Akihiko Yoshizawa, Gregory J Riely, W. Gerald, 2011, Modern Pathology.

A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma

Prasad S Adusumilli, Akihiko Yoshizawa, Gregory J Riely, 2012, Modern Pathology.

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Tae Min Kim, Bruce E Johnson, Harry J M Groen, 2016, The Lancet. Oncology.

Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease

Akihiko Yoshizawa, William D. Travis, C. Sima, 2014, The American journal of surgical pathology.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

William Pao, Stephen Broderick, Lu Wang, 2007, Proceedings of the National Academy of Sciences.

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

William Pao, Binsheng Zhao, Lawrence H Schwartz, 2007, Clinical Cancer Research.

ProspectiveAssessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by theAddition of Everolimus

L. Schwartz, Binsheng Zhao, M. Kris, 2007 .

Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC).

M. Ladanyi, M. Kris, W. Pao, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.

Binsheng Zhao, Chaya S Moskowitz, Pingzhen Guo, 2009, Radiology.

Reply to E.M. Gilles

L. Schwartz, Gregory Riely, G. Oxnard, 2012 .

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Ahmet Zehir, Ronglai Shen, Barry S Taylor, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers

M. Ladanyi, A. Drilon, C. Rudin, 2019, JCO precision oncology.

A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.

M. Kris, Gregory Riely, N. Rizvi, 2007, Lung cancer.

Non-small cell lung cancer.

D. Ettinger, M. Kris, G. Bepler, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

D. Ettinger, L. Chirieac, R. Govindan, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management.

A. Shaw, S. Ou, Gregory Riely, 2012 .

Placental protein 14 functions as a direct T-cell inhibitor.

Gregory Riely, M. Tykocinski, J. Rachmilewitz, 1999, Cellular immunology.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers.

Funda Meric-Bernstam, Jason Roszik, Vivek Subbiah, 2020, Cancer discovery.

Focal Localization of Placental Protein 14 Toward Sites of TCR Engagement1

Gregory Riely, M. Tykocinski, J. Rachmilewitz, 2002, The Journal of Immunology.

Concurrent genetic alterations identified by next-generation sequencing in pre-treatment, metastatic EGFR-mutant lung cancers.

M. Ladanyi, M. Berger, M. Kris, 2016 .

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers

Nikolaus Schultz, Charles M. Rudin, Matthew D. Hellmann, 2018, Clinical Cancer Research.

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

William Pao, Marc Ladanyi, Geoffrey R. Oxnard, 2010, Clinical Cancer Research.

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma.

M. Ladanyi, C. Sima, M. Kris, 2010 .

Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas.

Mark E. Robson, Matthew D. Hellmann, Marc Ladanyi, 2017, JCO precision oncology.

MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

Jeffrey W. Clark, A. Drilon, M. Socinski, 2017 .

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

L. Borsu, M. Ladanyi, A. Drilon, 2015, JAMA oncology.

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer

M. Ladanyi, A. Drilon, C. Rudin, 2019, JCO precision oncology.

Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor

M. Kris, M. Arcila, Gregory Riely, 2021, JCO precision oncology.

Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer

Gregory Riely, K. Arbour, 2018, Cancer.

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Geoffrey R. Oxnard, Ross A. Soo, Matthew Meyerson, 2013, Science Translational Medicine.

Structural, biochemical, and clinical characterization of Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in lung cancer (Science Translational Medicine (2014) 6, (225er1))

M. Meyerson, M. Hanna, L. Sequist, 2014 .

Pack years of cigarette smoking as a predictor of survival in 2,013 patients with stage IIIb/IV non-small cell lung cancer (NSCLC)

C. Sima, M. Kris, R. Shen, 2008 .

KRAS Mutations

M. Ladanyi, Gregory Riely, 2010 .

EGFR Mutations in Lung Adenocarcinomas

M. Ladanyi, M. Kris, W. Pao, 2010 .

EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial.

M. Ladanyi, M. Kris, W. Pao, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Non – Small Cell Lung Cancer, Version 3.2022

Joe Y. Chang, D. Ettinger, L. Chirieac, 2022 .

Bronchioloalveolar Carcinoma of the Lung

Gregory Riely, V. Miller, 2006 .

Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation

C. Begg, Gregory Riely, P. Sabbatini, 2022, JAMA network open.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Gregory Riely, D. Planchard, M. Hellmann, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deep learning to estimate RECIST in patients with NSCLC treated with PD-1 blockade.

R. Barzilay, S. Digumarthy, M. Kris, 2020, Cancer discovery.

A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations.

M. Kris, W. Pao, Gregory Riely, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.

A. Drilon, C. Sima, M. Zauderer, 2014, Lung cancer.

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

C. Sima, M. Kris, C. Azzoli, 2012, Clinical Cancer Research.

Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.

M. Kris, C. Azzoli, Gregory Riely, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer

Gregory Riely, V. Miller, 2007, Clinical Cancer Research.

Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.

V. Seshan, C. Rudin, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

M. Kris, Gregory Riely, G. Heller, 2021, JCO precision oncology.

Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers

David R. Jones, A. Drilon, C. Rudin, 2019, Cancer.

Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.

L. Schwartz, Binsheng Zhao, C. Sima, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).

A. Shaw, S. Gettinger, S. Ou, 2012 .

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.

L. Diaz, B. Nabet, Gregory Riely, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib.

M. Ladanyi, A. Drilon, C. Rudin, 2020, JCO precision oncology.

Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.

Thomas J. Smith, G. Giaccone, N. Hanna, 2017, Journal of oncology practice.

EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations.

W. Pao, K. Offit, Gregory Riely, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sequencing Therapy for Patients With Lung Cancer

Gregory Riely, 2020, Journal of the National Comprehensive Cancer Network.

Pack‐years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer

C. Sima, M. Kris, R. Shen, 2010, Cancer.

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

William Pao, Marc Ladanyi, Gregory J Riely, 2006, Clinical Cancer Research.

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

William Pao, Marc Ladanyi, Vincent A. Miller, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928)

M. Socinski, E. Smit, Gregory Riely, 2014 .

Differences in the survival of patients with recurrent versus de novo metastatic KRAS‐mutant and EGFR‐mutant lung adenocarcinomas

C. Sima, M. Kris, Gregory Riely, 2015, Cancer.

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.

R. Wilson, M. Ladanyi, M. Kris, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

M. Ladanyi, M. Kris, W. Pao, 2008, Clinical Cancer Research.

Negative Regulation of T Cell Activation by Placental Protein 14 Is Mediated by the Tyrosine Phosphatase Receptor CD45*

Gregory Riely, M. Tykocinski, J. Rachmilewitz, 2003, The Journal of Biological Chemistry.

Thymomas and thymic carcinomas

D. Ettinger, M. Kris, L. Chirieac, 2013 .

Comparison of patterns of relapse in thymic carcinoma and thymoma.

V. Rusch, W. Travis, M. Bains, 2009, The Journal of thoracic and cardiovascular surgery.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial

Michael Thomas, Armando Santoro, Martin Schuler, 2016, The Lancet. Oncology.

The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.

M. Socinski, Gregory Riely, R. Perez-soler, 2017, Clinical lung cancer.

Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC).

S. Gettinger, Gregory Riely, G. Weiss, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.

A. Bottomley, A. Shaw, T. Mok, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

M. Socinski, R. Govindan, Kwok-Kin Wong, 2007, Clinical Cancer Research.

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

Gregory J Riely, Bruce E Johnson, G. Giaccone, 2009, Clinical Cancer Research.

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

M. Ladanyi, A. Iafrate, M. Mino‐Kenudson, 2013, Clinical Cancer Research.

Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Iafrate, J. Engelman, 2013 .

Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases

M. Kris, W. Pao, Gregory Riely, 2018, Cancer.

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

M. Ladanyi, Michael Fara, C. Sima, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Specifying the True- and False-Positive Rates in Basket Trials.

Mithat Gönen, Kristen M Cunanan, Alexia Iasonos, 2017, JCO precision oncology.

alpha2-macroglobulin modulates the immunoregulatory function of the lipocalin placental protein 14.

Gregory Riely, M. Tykocinski, J. Rachmilewitz, 2000, The Biochemical journal.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

S. Gettinger, R. Heist, Gregory Riely, 2022, JTO clinical and research reports.

PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC).

A. Drilon, C. Rudin, M. Kris, 2017, Journal of Clinical Oncology.

Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

Gregory Riely, D. Aisner, 2021, Journal of the National Comprehensive Cancer Network.

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging

C. Sima, Gregory Riely, A. Moreira, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

M. Kris, Gregory Riely, M. Hellmann, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

N. Hanna, Gregory Riely, L. Gaspar, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.

A. Shaw, S. Ou, Gregory Riely, 2018 .

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

M. Socinski, A. Shaw, S. Ou, 2016, The Lancet. Oncology.

Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers.

M. Ladanyi, A. Drilon, C. Sima, 2015 .

Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.

A. Iafrate, A. Shaw, B. Yeap, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion

C. Sima, M. Kris, C. Azzoli, 2011, Cancer Chemotherapy and Pharmacology.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Donavan T. Cheng, Alexander V Penson, Benjamin E. Gross, 2017, Nature Medicine.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

胸腺恶性肿瘤化疗的相关定义和策略

N. Girard, H. Wakelee, Gregory Riely, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

thresholds A rheostatic mechanism for T-cell inhibition based on elevation of activation

Gregory Riely, M. Tykocinski, J. Rachmilewitz, 2010 .

Toward Sites of TCR Engagement Focal Localization of Placental Protein 14

Gregory Riely, J. Rachmilewitz, Mark, 2002 .

A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholds.

Gregory Riely, M. Tykocinski, J. Rachmilewitz, 2001, Blood.

Induction therapy for locally advanced thymoma.

Gregory Riely, James Huang, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.

T. Choueiri, M. Galsky, N. Nock, 2022, JAMA oncology.

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

M. Kris, Gregory Riely, M. Hellmann, 2019 .

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).

M. Socinski, A. Shaw, S. Ou, 2015 .

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

David R. Jones, N. Schultz, M. Ladanyi, 2021, Nature Medicine.

Multimodality therapy for locally advanced thymomas: state of the art or investigational therapy?

K. Rosenzweig, V. Rusch, Gregory Riely, 2008, The Annals of thoracic surgery.

Serplulimab With Chemotherapy in Extensive-Stage SCLC.

Gregory Riely, N. Choudhury, 2022, JAMA.

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer

M. Ladanyi, C. Rudin, M. Kris, 2021, Clinical Cancer Research.

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2021, JTO clinical and research reports.

A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers.

C. Sima, C. Rudin, M. Kris, 2015 .

The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma

Alex K. Williamson, Gregory Riely, D. Hanson, 2021, Journal of pediatric hematology/oncology.

Crizotinib Treatment in Patients (PTS) with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2013 .

Phase II study of cixutumumab (IMC-A12) in thymic malignancies.

G. Giaccone, Helen X. Chen, Gregory Riely, 2012 .

Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13.

M. Ladanyi, C. Sima, M. Kris, 2013 .

Small cell lung cancer (SCLC) among patients who are never smokers.

M. Berger, C. Sima, M. Kris, 2013 .

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers

A. Drilon, M. Kris, D. Carbone, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib.

M. Ladanyi, W. Pao, Gregory Riely, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Drilon, M. Socinski, 2016 .

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

P. Jänne, R. Heist, J. Christensen, 2022, The New England journal of medicine.

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer

Jie Yang, P. Jänne, Gregory Riely, 2022, Expert review of anticancer therapy.

Ef ﬁ cacy of Platinum/Pemetrexed Combination Chemotherapy in ALK -Positive NSCLC Refractory to Second-Generation ALK Inhibitors

S. Digumarthy, A. Shaw, Gregory Riely, 2020 .

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data

Gregory Riely, M. Bretscher, S. Mahrus, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Alokkumar Jha, M. Bonnen, S. Shete, 2020, The Lancet.

Targeting ALK: Precision Medicine Takes on Drug Resistance.

A. Shaw, Gregory Riely, Jessica J. Lin, 2017, Cancer discovery.

A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.

C. Sima, M. Kris, Gregory Riely, 2015 .

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Ruey-min Lee, S. Ou, Gregory Riely, 2014, The Lancet. Oncology.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

S. C. Wang, A. Iafrate, A. Shaw, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers

L. Borsu, M. Ladanyi, C. Rudin, 2019, Acta oncologica.

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer

M. Socinski, A. Shaw, Gregory Riely, 2015, The Lancet. Oncology.

Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology

Steven E. Schild, Renato Martins, Billy W. Loo, 2017 .

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

William Pao, Gregory J Riely, D Ross Camidge, 2014, Cancer discovery.

Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

C. Rudin, M. Socinski, Gregory Riely, 2013 .

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

B. Taylor, M. Ladanyi, C. Rudin, 2020, Clinical Cancer Research.

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.

N. Hanna, Gregory Riely, L. Gaspar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas

David R. Jones, M. Ladanyi, C. Rudin, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

B. Taylor, N. Schultz, M. Ladanyi, 2017, Cancer discovery.

Characteristics of Lung Cancers Harboring NRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2013, Clinical Cancer Research.

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma

M. Ladanyi, Gregory Riely, N. Rekhtman, 2013, Modern Pathology.

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

Ronglai Shen, Marc Ladanyi, M. Ladanyi, 2012, Clinical Cancer Research.

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

William Pao, Marc Ladanyi, Valerie Rusch, 2008, The Journal of molecular diagnostics : JMD.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

P. Jänne, Gregory Riely, E. Felip, 2021, JAMA oncology.

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.

J. Neal, Gregory Riely, D. Costa, 2021, Cancer discovery.

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

M. Berger, A. Drilon, C. Rudin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

M. Ladanyi, A. Drilon, C. Rudin, 2018, Cancer discovery.

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR‐Mutated Lung Cancers

M. Ladanyi, C. Rudin, M. Kris, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Non-Small Cell Lung Cancer, Version 6.2015.

D. Ettinger, L. Chirieac, R. Govindan, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Non-small cell lung cancer, version 1.2015.

Renato Martins, Thomas J Dilling, Billy W Loo, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Can IASLC/ATS/ERS subtype help predict response to chemotherapy in small biopsies of advanced lung adenocarcinoma?

W. Travis, Gregory Riely, 2014, European Respiratory Journal.

Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis

W. Gerald, V. Seshan, M. Kris, 2008, The American journal of surgical pathology.

Non-small cell lung cancer.

Renato Martins, Mohammad Jahanzeb, Eric Rohren, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

David R. Jones, N. Schultz, M. Ladanyi, 2021, Cell.

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

M. Ladanyi, C. Rudin, M. Kris, 2021, Clinical Cancer Research.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

N. Schultz, M. Ladanyi, D. Zelterman, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

M. Ladanyi, C. Sima, M. Kris, 2015, Cancer.

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling

M. Ladanyi, C. Sima, M. Kris, 2011, Molecular Cancer Therapeutics.

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.

M. Ladanyi, C. Rudin, W. Travis, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.

Gregory Riely, K. Arbour, 2019, JAMA.

Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas.

V. Seshan, M. Ladanyi, M. Berger, 2019, JCO precision oncology.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

A. Drilon, C. Rudin, M. Kris, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

M. Ladanyi, M. Berger, M. Kris, 2018, Clinical Cancer Research.

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer

M. Ladanyi, M. Berger, C. Rudin, 2017, Clinical Cancer Research.

Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Renato Martins, Thomas J Dilling, Steven E Schild, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development

P. Jänne, R. Govindan, R. Herbst, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

M. Ladanyi, C. Sima, M. Kris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

D. Pe’er, M. Ladanyi, M. Kris, 2020, Clinical Cancer Research.

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

M. Kris, P. Jänne, W. Pao, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

M. Ladanyi, M. Kris, W. Pao, 2012, Cancer discovery.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

William Pao, Hongbin Ji, Nicolas Girard, 2011, European Respiratory Journal.

Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

W. Pao, Gregory Riely, V. Miller, 2006, Clinical Cancer Research.

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

M. Ladanyi, W. Pao, Gregory Riely, 2008, Clinical Cancer Research.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

A. Shaw, S. Ou, Gregory Riely, 2018, The Lancet. Oncology.

Insulin-Like Growth Factor-1 Receptor Expression in Thymic Malignancies

N. Girard, M. Kris, V. Rusch, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer.

M. Berger, S. Gnerre, J. Reis-Filho, 2017 .

Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes.

D. Pe’er, M. Ladanyi, C. Rudin, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Diverse alterations associated with resistance to KRAS(G12C) inhibition

M. Berger, J. Reis-Filho, B. Weigelt, 2021, Nature.

KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

David R. Jones, S. Sihag, A. Drilon, 2021, Clinical Cancer Research.

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

M. Ladanyi, A. Drilon, M. Kris, 2020, Clinical Cancer Research.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Lucio Crinò, Benjamin Solomon, Patrick Schnell, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas

N. Girard, A. Lash, A. Viale, 2009, Clinical Cancer Research.

Malignant pleural mesothelioma.

D. Ettinger, M. Kris, L. Chirieac, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.

G. Giaccone, S. Steinberg, Helen X. Chen, 2014, The Lancet. Oncology.

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

Gregory Riely, N. Rekhtman, A. Moreira, 2017, PloS one.

Management and outcomes of relapse after treatment for thymoma and thymic carcinoma.

V. Rusch, W. Travis, M. Bains, 2011, Annals of Thoracic Surgery.

Massively Parallel Sequencing Identifies Recurrent Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis

M. Ladanyi, M. Berger, Gregory Riely, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Thomas J. Smith, Thomas J Smith, Gregory J Riely, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SMARCA4 inactivation promotes lineage-specific transformation and early metastatic features in the lung.

Jason D. Buenrostro, Vinay K. Kartha, Francisco J. Sánchez-Rivera, 2021, Cancer discovery.

Acquired Resistance to KRASG12C Inhibition in Cancer.

P. Jänne, D. Root, R. Heist, 2021, The New England journal of medicine.

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2013, Cancer.

Germline EGFR T790M mutation found in multiple members of a familial cohort.

M. Ladanyi, M. Berger, M. Robson, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive Biomarkers and Personalized Medicine Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer : Distinct Natural History of Patients with Tumors Harboring the T 790 M Mutation

M. Ladanyi, C. Sima, M. Kris, 2011 .

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

M. Ladanyi, M. Kris, W. Pao, 2011, Clinical Cancer Research.

NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer

D. Ettinger, M. Kris, L. Chirieac, 2014 .

NCCN Non – Small Cell Lung Cancer Clinical Practice Guidelines in Oncology

D. Ettinger, M. Kris, G. Bepler, 2010 .

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

A. Shaw, S. Ou, Gregory Riely, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

P. Jänne, D. Haber, L. Sequist, 2015, Clinical Cancer Research.

Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Gregory Riely, C. Lovly, Helena A. Yu, 2014, Clinical Cancer Research.

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.

M. Ladanyi, M. Kris, M. Arcila, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

C. Sima, M. Kris, C. Azzoli, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cancer Growth Factor Receptor ( EGFR ) Exon 20 Insertion Mutations in Lung Structural , Biochemical , and Clinical Characterization of Epidermal

M. Meyerson, M. Hanna, L. Sequist, 2013 .

Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations

M. Kris, D. Tenen, W. Pao, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

P. Jänne, D. Tenen, W. Pao, 2008, Clinical Cancer Research.

Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens

W. Travis, Gregory Riely, M. Zakowski, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Jeffrey W. Clark, A. Iafrate, S. Fox, 2012, The Lancet. Oncology.

Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis.

David R. Jones, V. Rusch, M. Bains, 2020, The Journal of thoracic and cardiovascular surgery.

Defining the immunologic phenotype of thymic epithelial tumors.

C. Sima, J. Wolchok, Gregory Riely, 2015 .

[Chemotherapy definitions and policies for thymic malignancies].

N. Girard, H. Wakelee, Gregory Riely, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group

Gregory Riely, F. Detterbeck, A. Rimner, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

C. Sima, C. Rudin, M. Kris, 2016, Clinical lung cancer.

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

David R. Jones, M. Ladanyi, E. Hubbell, 2019, Nature Medicine.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

S. C. Wang, A. Iafrate, A. Shaw, 2019 .

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

M. Ladanyi, A. Drilon, M. Kris, 2015, Clinical Cancer Research.

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

M. Ladanyi, C. Sima, C. Rudin, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

M. Ladanyi, C. Sima, M. Kris, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.

S. Digumarthy, A. Shaw, B. Yeap, 2018 .

Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

M. Ladanyi, A. Drilon, Shunqi Yan, 2016, Clinical Cancer Research.

Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology.

D. Ettinger, M. Kris, L. Chirieac, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

William Pao, Yumei Pan, Lu Wang, 2012, Proceedings of the National Academy of Sciences.

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

M. Ladanyi, C. Sima, M. Kris, 2011, Clinical Cancer Research.

Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach

David R. Jones, V. Seshan, M. Ladanyi, 2019, Clinical Cancer Research.

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

William Pao, Maria E Arcila, Gregory J Riely, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

R. Gray, K. Flaherty, L. Rubinstein, 2020, Clinical Cancer Research.

Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers

N. Socci, S. Lowe, J. Reis-Filho, 2022 .

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

P. Jänne, S. Ou, R. Heist, 2021 .

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

D. Ettinger, L. Chirieac, R. Govindan, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines

Renato Martins, Eric M. Rohren, Billy W. Loo, 2013 .

The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification

J. Austin, A. Nicholson, I. Petersen, 2009 .

Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

L. Sequist, Gregory Riely, E. Felip, 2020, The Lancet. Respiratory medicine.

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab

C. Sima, M. Kris, V. Rusch, 2013, Cancer Chemotherapy and Pharmacology.

Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2014 .

Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples.

L. Borsu, M. Ladanyi, M. Arcila, 2016, The Journal of molecular diagnostics : JMD.

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer

Gregory Riely, Helena A. Yu, H. Yu, 2015, Clinical Cancer Research.

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.

Gregory Riely, Helena A. Yu, H. Yu, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Predictive Biomarkers and Personalized Medicine Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T 790 M Mutation Using a Locked Nucleic Acid-Based Assay

M. Ladanyi, M. Kris, W. Pao, 2011 .

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Renato Martins, Joe Y. Chang, Thomas J Dilling, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Gregory Riely, K. Arbour, 2017, Hematology/oncology clinics of North America.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

P. Jänne, S. Ou, Gregory Riely, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma

Gregory Riely, S. Ha, B. Cho, 2013, Yonsei medical journal.

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

H. Varmus, M. Ladanyi, M. Kris, 2018, Proceedings of the National Academy of Sciences.

YES1 amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

H. Varmus, M. Ladanyi, M. Kris, 2018, bioRxiv.

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.

C. Sima, C. Rudin, M. Kris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR‐Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib

M. Kris, Gregory Riely, J. Bromberg, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

B. B. Weitner, A. Rademaker, M. Kris, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.

Gregory Riely, 2008, Lung cancer.

Predictive Biomarkers and Personalized Medicine ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS : An Analysis of 1 , 683 Patients with Non – Small Cell Lung Cancer

M. Ladanyi, A. Iafrate, M. Mino‐Kenudson, 2013 .

KRAS mutations: an old oncogene becomes a new predictive biomarker.

M. Ladanyi, Gregory Riely, 2008, The Journal of molecular diagnostics : JMD.

KRAS mutational testing in the selection of patients for EGFR-targeted therapies.

M. Ladanyi, K. Nafa, Gregory Riely, 2008, Seminars in diagnostic pathology.

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.

G. Scagliotti, M. Mino‐Kenudson, J. Engelman, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Incorporation of crizotinib into the NCCN guidelines.

M. Ladanyi, M. Kris, Gregory Riely, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

NovelD761YandCommonSecondary T790MMutationsinEpidermal Growth Factor Receptor^Mutant LungAdenocarcinomaswith AcquiredResistance toKinase Inhibitors

M. Ladanyi, M. Kris, W. Pao, 2006 .

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.

David R. Jones, L. Borsu, M. Ladanyi, 2018, Journal of the National Cancer Institute.

HER2 Amplifi cation: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR

M. Ladanyi, M. Kris, E. Stanchina, 2012 .

HER 2 Amplifi cation : A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR T 790 M Mutation

M. Ladanyi, M. Kris, E. Stanchina, 2012 .

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration

Jeffrey W. Clark, A. Drilon, R. Heist, 2019, Nature Medicine.

Lungs Don’t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers

M. Ladanyi, C. Sima, M. Kris, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design.

E. Smit, M. Ahn, Gregory Riely, 2021, Future oncology.

Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer

J. Warner, Gregory Riely, D. Schrag, 2021, JAMA network open.

Automated NLP Extraction of Clinical Rationale for Treatment Discontinuation in Breast Cancer.

D. Sontag, Gregory Riely, P. Razavi, 2021, JCO clinical cancer informatics.

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.

Julie L. Yang, M. Ladanyi, M. Berger, 2020, JAMA oncology.

Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors.

S. Digumarthy, A. Shaw, B. Yeap, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer in 'Never-smokers': molecular factors trump risk factors.

Gregory Riely, 2010, Oncology.

Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer

Gregory Riely, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive Biomarkers and Personalized Medicine Characteristics of Lung Cancers Harboring NRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2013 .

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

M. Kris, C. Azzoli, W. Pao, 2011, Clinical Cancer Research.

Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

Gregory Riely, A. Rimner, Zhigang Zhang, 2017, Lung cancer.

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.

Andreas Rimner, Yoshiya Yamada, Abraham J Wu, 2014, International journal of radiation oncology, biology, physics.

Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, T. Lynch, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene.

Gregory Riely, P. Bray, M. Villa-García, 1994, Blood.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

C. Brennan, M. Ladanyi, M. Berger, 2019, Nature Genetics.

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer

M. Kris, C. Azzoli, W. Pao, 2007, Cancer.

Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers

A. Drilon, C. Rudin, M. Kris, 2021, British Journal of Cancer.

Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study

J. Blay, J. Baselga, Gregory Riely, 2019, JCO precision oncology.

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

M. Ladanyi, A. Drilon, C. Rudin, 2016, The Lancet. Oncology.

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

M. Ladanyi, A. Drilon, C. Rudin, 2016, The Lancet. Oncology.

Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?

Gregory Riely, M. Ginsberg, Junting Zheng, 2017, Clinical imaging.

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

C. Sima, M. Kris, Gregory Riely, 2011, Clinical Cancer Research.

Malignant Pleural MesotheliomaPractice Guidelines in Oncology

D. Ettinger, M. Kris, L. Chirieac, 2012 .

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

S. Gettinger, R. Heist, S. Ou, 2018 .

Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.

M. Ladanyi, M. Berger, C. Rudin, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

G. Mills, M. Ladanyi, C. Paweletz, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.

M. Ladanyi, A. Drilon, C. Rudin, 2018, JCO precision oncology.

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

C. Sima, M. Kris, V. Rusch, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Gregory Riely, R. Hui, K. Park, 2018, Journal of Thoracic Oncology.

Failure Patterns Relative to Radiation Treatment Fields for Stage II–IV Thymoma

E. Yorke, K. Rosenzweig, D. Gomez, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer.

C. Rudin, V. Rusch, R. Perez-Johnston, 2022, Clinical Cancer Research.

Estimation of the likelihood of epidermal growth factor receptor (EGFR) mutations based on cigarette smoking history in patients with adenocarcinoma of the lung

R. Wilson, M. Kris, V. Rusch, 2005 .

Non-small cell lung cancer, version 2.2013.

Renato Martins, Billy W Loo, Gregory J Riely, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

C. Sima, M. Kris, C. Azzoli, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

COVID-19 in patients with lung cancer

A. Drilon, M. Zauderer, C. Rudin, 2020, Annals of Oncology.

NCCN Non – Small Cell Lung Cancer , Version 1 . 2015 Clinical Practice Guidelines in Oncology

D. Ettinger, M. Kris, L. Chirieac, 2014 .

MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion-positive lung cancer.

M. Ladanyi, A. Drilon, Gregory Riely, 2022, Molecular cancer research : MCR.

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer

M. Socinski, S. Ou, A. Shaw, 2018, ESMO Open.

Brigatinib in Patients With Alectinib‐Refractory ALK‐Positive NSCLC

S. Digumarthy, A. Shaw, B. Yeap, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

N. Socci, M. Berger, S. Lowe, 2022, Cancer discovery.

Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.

Gregory Riely, D. Planchard, M. Hellmann, 2018 .

ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.

M. Ladanyi, Gregory Riely, N. Rekhtman, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma: Invasive Mucinous Pattern and Extracellular Mucin Are Associated With KRAS Mutation

Prasad S Adusumilli, Deborah Kuk, Yi-Chen Yeh, 2014, The American journal of surgical pathology.

A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.

David R. Jones, N. Schultz, M. Ladanyi, 2020, JAMA surgery.

Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.

L. Sequist, Gregory Riely, E. Felip, 2016 .

Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.

David R. Jones, M. Berger, C. Rudin, 2021, Lung cancer.

Who should receive EGFR tyrosine-kinase inhibitors?

Gregory Riely, Helena A. Yu, H. Yu, 2012, The Lancet. Oncology.

NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

A. Shaw, S. Ou, Gregory Riely, 2019, The Lancet. Oncology.

Response to erlotinib and prognosis for patients with de novo epidermal growth factor receptor (EGFR) T790M mutations.

M. Ladanyi, M. Kris, M. Arcila, 2013 .

P1.14-50 A Phase 2 Trial of Cabozantinib in ROS1-Rearranged Lung Adenocarcinoma

M. Ladanyi, A. Drilon, M. Kris, 2019, Journal of Thoracic Oncology.

Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.

N. Schultz, J. Warner, R. Shen, 2021, JAMA oncology.

Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?

Chaya S Moskowitz, Gregory J Riely, Gregory Riely, 2014, Lung cancer.

First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.

L. Sequist, Gregory Riely, E. Felip, 2015 .

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

C. Rudin, S. Gettinger, R. Heist, 2023, ESMO open.

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers

M. Ladanyi, A. Drilon, M. Kris, 2019, Cold Spring Harbor molecular case studies.

Phase II trial of bortezomib in KRAS G12D mutant lung cancers.

A. Drilon, M. Kris, Gregory Riely, 2015 .

A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.

C. Schumann, S. Gettinger, Gregory Riely, 2012 .

Non-small cell lung cancer.

Renato Martins, Mohammad Jahanzeb, Billy W Loo, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors.

Gregory Riely, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Conventional and radiomic features to predict pathology in the preoperative assessment of anterior mediastinal masses.

R. Perez-Johnston, P. Gibbs, Gregory Riely, 2023, Lung cancer.

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

M. Ladanyi, E. Hubbell, C. Rudin, 2019, Nature Medicine.

Clinical experience of cerebrospinal fluid-based liquid biopsy demonstrates superiority of cell free DNA over cell pellet genomic DNA for molecular profiling.

M. Ladanyi, M. Berger, M. Kris, 2021, The Journal of molecular diagnostics : JMD.

Type A thymoma presenting with bone metastasis

C. Antonescu, W. Travis, M. Bains, 2018, Histopathology.

Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Efficacy of PD-(L)1 Blockade Monotherapy Compared to PD-(L)1 Blockade Plus Chemotherapy in First-Line PD-L1-Positive Advanced Lung Adenocarcinomas

M. Ladanyi, C. Rudin, M. Kris, 2022, medRxiv.

Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial

M. Kris, C. Azzoli, W. Pao, 2007 .

SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors

M. Ladanyi, S. Toyooka, Gregory Riely, 2022, JCO precision oncology.

Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes

M. Ladanyi, M. Berger, M. Kris, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of the KRAS/EGFR mutation profile and survival of “collegiate smokers” and never smokers with advanced lung cancers.

M. Ladanyi, A. Drilon, C. Sima, 2012 .

Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions

P. Jänne, J. Neal, Gregory Riely, 2019, Annals of Oncology.

Screening for EGFR, KRAS, and PIK3CA mutations in well-characterized, immunohistochemically confirmed squamous cell carcinoma of lung.

M. Ladanyi, M. Kris, M. Arcila, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma.

A. Lash, M. Ladanyi, M. Kris, 2010 .

Genomic mapping of metastatic organotropism in lung adenocarcinoma.

N. Schultz, M. Berger, C. Rudin, 2023, Cancer cell.

MA19.09 Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB

C. Rudin, R. Shen, Gregory Riely, 2018, Journal of Thoracic Oncology.

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.

G. Mills, M. Ladanyi, C. Paweletz, 2019 .

Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium

G. Mills, M. Ladanyi, C. Paweletz, 2016 .

Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).

A. Shaw, S. Ou, Gregory Riely, 2019, Journal of Clinical Oncology.

988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)

P. Jänne, Gregory Riely, T. Mekhail, 2022, Annals of Oncology.

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

Gregory Riely, E. Felip, P. Janne, 2021 .

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

M. Kris, W. Pao, J. Warner, 2010 .

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.

L. Sequist, E. Smit, Gregory Riely, 2022, European journal of cancer.

OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

S. C. Wang, A. Drilon, R. Heist, 2018, Journal of Thoracic Oncology.

Association of outcomes and co-occuring genomic alterations in patients with KRAS-mutant non-small cell lung cancer.

M. Ladanyi, M. Berger, M. Kris, 2016 .

Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer.

C. Begg, Gregory Riely, P. Sabbatini, 2022, JAMA oncology.

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Philip S. Yu, Sharon S. Choi, Omar H. Butt, 2023, BMC Cancer.

Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.

D. Pe’er, M. Ladanyi, M. Kris, 2019, Journal of Clinical Oncology.

CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors.

P. Gibbs, Gregory Riely, M. Ginsberg, 2021, The Annals of thoracic surgery.

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

P. Jänne, S. Ou, R. Heist, 2020 .

EGFR mutations in men and cigarette smokers with lung adenocarcinoma.

M. Ladanyi, M. Kris, V. Rusch, 2010 .

OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers

M. Ladanyi, M. Berger, C. Rudin, 2017 .

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

Allison P. Heath, Marilyn M. Li, Jena V. Lilly, 2022, Scientific Reports.

Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC).

S. Gettinger, Gregory Riely, B. Solomon, 2013 .

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer ( NSCLC ) : updated results from the phase 1 , multicentre , open-label ASCEND-1 trial

Michael Thomas, A. Shaw, Gregory Riely, 2016 .

Management of Patients With Resectable and Metastatic Non–Small Cell Lung Cancer

Gregory Riely, J. Yanagawa, 2022, The Journal of the National Comprehensive Cancer Network.

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

S. Ou, R. Heist, J. Christensen, 2022, Journal of Clinical Oncology.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.

A. Drilon, C. Sima, M. Kris, 2012 .

Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers.

A. Drilon, M. Kris, D. Carbone, 2017 .

Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI).

M. Ladanyi, M. Kris, W. Pao, 2010 .

Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.

J. Neal, Gregory Riely, D. Costa, 2019, Journal of Clinical Oncology.

COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease

E. Robilotti, T. Choueiri, Gregory Riely, 2023, Translational oncology.

Acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer.

William Pao, Marc Ladanyi, Vincent A. Miller, 2006 .

MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

M. Socinski, A. Shaw, S. Ou, 2017 .

OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations

P. Jänne, Gregory Riely, E. Felip, 2021 .

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations.

M. Kris, C. Azzoli, Gregory Riely, 2009, Journal of Clinical Oncology.

Abstract B015: An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer

M. Berger, S. Lowe, J. Reis-Filho, 2018 .

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.

Jie Yang, Gregory Riely, P. Janne, 2022, Journal of Clinical Oncology.

A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).

B. B. Weitner, A. Rademaker, E. Hart, 2013 .

Multimodality Therapy for Locally Advanced Thymomas: State of the Art or

K. Rosenzweig, V. Rusch, Gregory Riely, 2010 .

Molecular on/off switch.

M. Kris, W. Pao, Gregory Riely, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brief report: Combination of Osimertinib and Dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas.

M. Ladanyi, M. Kris, Gregory Riely, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

M. Ladanyi, C. Rudin, M. Kris, 2023, Journal for ImmunoTherapy of Cancer.

Investigation of patterns of nodal metastases in BRAF mutant lung cancer.

Gregory Riely, M. Ginsberg, D. Halpenny, 2017, Lung cancer.

A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach

J. Warner, Gregory Riely, B. Park, 2022, JCO clinical cancer informatics.

A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ).

G. Scagliotti, A. Shaw, S. Gettinger, 2012 .

1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)

P. Jänne, J. Neal, Gregory Riely, 2020 .

P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

P. Jänne, J. Neal, Gregory Riely, 2018, Journal of Thoracic Oncology.

Management of thymoma‐associated pure red cell aplasia: A novel use of blood substitute HBOC‐201 in a Jehovah’s Witness

Gregory Riely, S. Avecilla, G. Dubé, 2019, Clinical case reports.

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2

Gregory Riely, S. Temin, P. Ellis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and genomic predictors of brain metastases (BM) in non-small cell lung cancer (NSCLC): An AACR Project GENIE analysis.

Neha M Jain, N. Schultz, J. Warner, 2021 .

Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).

J. Barretina, L. Sequist, Gregory Riely, 2017 .

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

P. Jänne, Gregory Riely, S. Ramalingam, 2021, Journal of Clinical Medicine.

P1.04-39 Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers

A. Drilon, C. Rudin, M. Kris, 2019, Journal of Thoracic Oncology.

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.

M. Ladanyi, C. Rudin, M. Kris, 2023, The oncologist.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Donavan T. Cheng, Benjamin E. Gross, Michael H. Eubank, 2017, Nature Network Boston.

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer

M. Ladanyi, R. Shen, Gregory Riely, 2023, JCO precision oncology.

Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

Jie Yang, Gregory Riely, F. de Marinis, 2023, Journal of Clinical Oncology.

Targeted Therapy for Metastatic Non–Small Cell Lung Cancer

Gregory Riely, 2023, Journal of the National Comprehensive Cancer Network.

Chemotherapy definitions and policies for thymic malignancies.

N. Girard, H. Wakelee, Gregory Riely, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6

A. Shaw, S. Ou, Gregory Riely, 2018, Journal of Thoracic Oncology.

Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials.

M. Ladanyi, A. Drilon, M. Kris, 2013 .

Reproducibility of computed tomography (CT) measurements of lung cancer

L. Schwartz, Binsheng Zhao, M. Kris, 2008 .

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2

Nofisat Ismaila, Gregory Riely, I. Jaiyesimi, 2023, Journal of Clinical Oncology.

Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay.

M. Ladanyi, M. Berger, A. Drilon, 2015 .

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

D. Ettinger, L. Chirieac, R. Govindan, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

COVID-19 Severity and Cardiovascular Outcomes in SARS-COVID-19 Severity and Cardiovascular Outcomes in SARS-CoV-2-Infected Patients With Cancer and Cardiovascular Disease CoV-2-Infected Patients With Cancer and Cardiovascular Disease

E. Robilotti, T. Choueiri, Gregory Riely, 2023 .

OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy

Duc Minh Nguyen, P. Jänne, J. Neal, 2021, Journal of Thoracic Oncology.

Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.

W. Pao, Gregory Riely, R. Doebele, 2019, Journal of Clinical Oncology.

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

M. Ladanyi, C. Sima, C. Rudin, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

M. Kris, C. Azzoli, W. Pao, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

J. Austin, I. Petersen, V. Rusch, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

M. Ladanyi, C. Sima, M. Kris, 2013, Clinical Cancer Research.

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

H. Groen, W. Pao, E. Smit, 2014, Cancer discovery.

First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).

P. Jänne, J. Neal, Gregory Riely, 2018 .

W. Gerald, V. Seshan, M. Kris, 2008, The American journal of surgical pathology.

Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.

Gregory Riely, M. Ginsberg, M. Capanu, 2017, Lung cancer.

Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

M. Ladanyi, A. Drilon, C. Rudin, 2016 .

Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes

M. Ladanyi, M. Berger, M. Kris, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

E. Smit, M. Ahn, Gregory Riely, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

G. Scagliotti, M. Mino‐Kenudson, J. Engelman, 2021 .

A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers.

M. Kris, Gregory Riely, R. Young, 2017 .

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

David R. Jones, N. Schultz, M. Ladanyi, 2022, Nature Medicine.

Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research

Gregory Riely, M. Hellmann, P. Sabbatini, 2021, Cancer Cell.

Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

L. Chirieac, Gregory Riely, T. Dilling, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Non-small cell lung cancer.

M. Kris, G. Bepler, L. Chirieac, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.

Gregory Riely, 2008, Lung cancer.

Non-small Cell Lung Cancer

M. Kris, G. Bepler, L. Chirieac, 2013, International Manual of Oncology Practice.

ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.

M. Ladanyi, Gregory Riely, N. Rekhtman, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal

Allison P. Heath, Benjamin E. Gross, Stuart M. Gardos, 2023, Cancer research.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

M. Ladanyi, M. Kris, W. Pao, 2012, Cancer discovery.

Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors

Gregory Riely, A. Louissaint, J. Ackman, 2024, The oncologist.

EGFR mutation, immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC

M. Ladanyi, M. Kris, W. Pao, 2005 .

Nccn Clinical Practice Guidelines in Oncology™ Non-small Cell Lung Cancer Practice Guidelines in Oncology – V.2.2010 Non-small Cell Lung Cancer Nccn Non-small Cell Lung Cancer Panel Members Roswell Park Cancer Institute Memorial Sloan-kettering Cancer Center Continue Nccn Guidelines Panel Disclosure

M. Kris, G. Bepler, L. Chirieac, 2022 .

A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer

C. Rudin, M. Kris, C. Azzoli, 2007 .